浙江永太科技股份有限公司投资者关系活动记录表 证券代码：002326 证券简称：永太科技 编号：20151126 | --- | --- | --- | |-------------------------|--------------------------------|-----------------------------------------------------------------------| | | | | | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | 媒体采访 | 业绩说明会 | | 类别 | 新闻发布会 | 路演活动 | | | 现场参观 | 其他 | | 参与单位名称及 人员姓名 | 淡水泉（北京）投资管理有限公司 | 叶智深 | | 时间 2015 | 年 11 月 26 日 | 上午 10:00 | | 地点 | 公司总部 | | | 上市公司接待人 员姓名 | 董事会秘书 戴涛 | | | | 1. 公司 2015 | 全年业绩预计如何？ | | | | 公司预计全年销售收入将继续稳定增长，归属于上市公司股东 | | | 的净利润增长幅度在 | 80%- ...

浙江永太科技股份有限公司投资者关系活动记录表 证券代码：002326 证券简称：永太科技 编号：20151208 | --- | --- | --- | |------------------------------|---------------------------------------------------------|-----------------------------------------------------------------------| | \n投资者关系活动 \n类别 \n | 特定对象调研 \n 媒体采访 \n 新闻发布会 \n 现场参观 | 分析师会议 \n 业绩说明会 \n 路演活动 \n 其他 | | 参与单位名称及 人员姓名 | | 东北证券股份有限公司上海证券研究咨询分公司 张明烨 | | 时间 2015 | 年 12 月 08 日 | 上午 10:00 | | 地点 公司总部 | | | | 上市公司接待人 员姓名 | 董事会秘书 戴涛 | | | | 1.公司 2015 | 全年业绩预计如何？ | | | | 公司预计全年销售收入将继续稳定增长，归属于上 ...

浙江永太科技股份有限公司投资者关系活动记录表 证券代码：002326 证券简称：永太科技 编号：20150821 | --- | --- | --- | |----------------|----------------------------|----------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | | 媒体采访 业绩说明会 | | 类别 | 新闻发布会 路演活动 | | | | 现场参观 其他 | | | 参与单位名称及 | 中大投资 | 郑秀峰，恒益富通投资 王钱，沃金投资 熊适时 | | 人员姓名 | 陈周盛 ，毕咸投资 | 陈光 | | 时间 | 2015 年 8 月 21 | 日 下午 13:30 | | 地点 | 公司总部 | | | 上市公司接待人 | 董事会秘书 关辉 | | | 员姓名 | 证券投资部经理 | 戴涛 | | | 证券事务代表 | 陈丽萍 | | 投资者关系活动 | 1. 公司 2015 | 年半年度业绩以及三季度的业绩预计如何？ | | 主要内容介绍 | 报 ...

Group 1: Financial Performance - The net profit attributable to shareholders for the first half of 2016 is projected to be between RMB 11,066.12 million and RMB 14,385.96 million, representing a year-on-year growth of 0%-30% [1] - The company expects to achieve a net profit of no less than RMB 1.2 billion over the next three years, and with the performance commitments from Zhejiang Handxin and Foshan Handxin, the net profit could reach no less than RMB 1.4 billion [1] Group 2: Profit Commitment - The actual controllers of the company have publicly committed that if the cumulative net profit from 2016 to 2018 is less than RMB 1.2 billion, they will make up the difference in cash within 10 working days after the 2018 audit report is disclosed [2] - The promised profit from Zhejiang Handxin and Foshan Handxin (calculated at 90% for Foshan Handxin) for the years 2016 to 2018 is not less than RMB 224.8 million [2] Group 3: Product Development - The company's CF photoresist products can be applied in the production of OLED products, with ongoing technical research and development in collaboration with Huaxing Optoelectronics, aiming for mass production this year [2] - The acquisition of Zhejiang Handxin and Foshan Handxin aims to enhance profitability, integrate the pharmaceutical industry chain, reduce risks in entering the raw material and formulation markets, and improve the company's pharmaceutical sector layout [2]

Group 1: Financial Projections - The project for lithium hexafluorophosphate is expected to generate an annual revenue of 940 million CNY and a net profit of 93.31 million CNY after reaching full production capacity [1] - The total investment for the first phase of the project is 387.6 million CNY, with a construction period of approximately 1.5 years [1] Group 2: Company Performance - For the first three quarters of 2016, the company reported an operating income of 1,308.33 million CNY and a net profit attributable to shareholders of 122.76 million CNY [2] Group 3: Project Development - The company is in the process of a major asset restructuring, which has been conditionally approved by the China Securities Regulatory Commission as of August 31, 2016 [2]

Group 1: Project Overview - The company has focused on the fine chemical field of fluorobenzene since its establishment, becoming a leading enterprise in this sector with core technologies for producing lithium hexafluorophosphate and new generation fluorinated electrolyte materials [1] - The project is located in Fujian Province's "12th Five-Year" fluorinated chemical industry development base, benefiting from good infrastructure and complete industrial support [1] - The project partner, Yongjing Chemical, is a large fluorochemical production enterprise in Fujian with rich experience and sufficient raw material supply capabilities [1] Group 2: Project Progress - The production workshop has completed equipment debugging and trial production reporting, and trial production work has been initiated [2] - After the trial production starts, the company can apply for factory inspections from potential customers and submit mass production samples to secure orders [2] Group 3: Market Expectations - According to the latest national policies on new energy vehicles, the market for new energy vehicles is expected to expand further, driving growth in related upstream materials [2] - The market demand for lithium hexafluorophosphate is anticipated to continue increasing due to the expansion of the new energy vehicle market [2]

Group 1: Company Overview - The company is a leading manufacturer of fluorobenzene fine chemicals with a complete product chain and global production capacity [1] - In the first nine months of 2019, the company achieved sales revenue of CNY 266,808.14 million, a year-on-year increase of 26.18% [1] - The net profit from non-recurring gains and losses was CNY 27,128.43 million, up 71.84% year-on-year, driven by abundant orders and improved gross profit margin [2] Group 2: Core Competencies - The majority of the company's product varieties can be sold independently, showcasing strong market adaptability and significant potential for product structure upgrades [2] - The company has implemented a production model that utilizes by-products to create higher-value products, reducing overall production costs [2] - The company follows a growth strategy of "internal growth and external expansion," extending its pharmaceutical and pesticide chains into high-value downstream areas [2][3] Group 3: Future Development Strategy - The company aims to enhance existing production facilities, improve management levels, and increase R&D and environmental standards [3] - There is a focus on deepening relationships with key customers and exploring their needs to ensure sustainable internal growth [3] - The company plans to leverage its capital market advantages for both internal growth and external development [3] Group 4: Market Prospects and Product Development - The lithium difluorosulfamide has a promising market outlook due to its advantages over lithium hexafluorophosphate, despite current reliance on imports [4] - The production workshop for lithium difluorosulfamide is progressing well, with small-scale production and ongoing product certification discussions with downstream clients [4] - The approval of Rosuvastatin Calcium Tablets by the FDA marks the company's qualification to sell in the U.S. market, positively impacting its performance [4] Group 5: Future Growth Points - The company anticipates steady growth from traditional products and collaborative development across its entire industrial chain [5] - Multiple projects are set to commence production, ensuring the company enters a fast growth phase, including the upcoming launch of lithium difluorosulfamide [5] - The ongoing construction of production bases in areas like Linhai and planned investments in Inner Mongolia will enhance the company's competitive edge in the fine chemical sector [5]

浙江永太科技股份有限公司投资者关系活动记录表 证券代码：002326 证券简称：永太科技 编号：20191203 | --- | --- | --- | |-----------------------|----------------------------|--------------------------------------------------------| | | 特定对象调研 | 分析师会议 | | 投资者关系活动 | 媒体采访 业绩说明会 | | | 类别 | 新闻发布会 路演活动 | | | | 现场参观 其他 | | | 参与单位名称及 | 华安基金管理有限公司 周阳 | | | 人员姓名 | 国金证券股份有限公司 | 许菲菲 | | | 光大保德信基金管理有限公司 | 苏淼 | | | 中欧基金管理有限公司 | 王建礼 | | | 海通证券股份有限公司 | 孙维容 | | 时间 | 2019 年 12 月 03 | 日 | | 地点 | 浙江手心制药有限公司会议室 | | | 上市公司接待人 员姓名 | 何匡、张江山 | | | 投资者关系活动 | 一、介绍公司的经营情况 | | ...

Group 1: Company Overview - Zhejiang Yongtai Technology Co., Ltd. is a leading manufacturer of fluorobenzene fine chemicals with a complete product chain and global production capacity [1] - The company operates in pharmaceuticals, pesticides, and electronic chemicals, providing high-quality products and services to domestic and international clients [1] Group 2: Financial Performance - In the first half of 2020, the company achieved operating revenue of CNY 158,671.02 million, a decrease of 5.59% year-on-year [2] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was CNY 11,005.14 million, down 21.27% year-on-year [2] - In Q2 2020, the company reported sales revenue of CNY 107,911.88 million, an increase of 14.44% year-on-year, and a net profit of CNY 12,092.55 million, up 26.75% year-on-year, indicating recovery from the pandemic's impact [2] Group 3: Core Competencies - The company leverages its fluorination technology, chiral enzyme catalysis, and green reaction technology to extend its pharmaceutical and pesticide chains into high-value downstream products [3] - It has established a strict quality management system and has obtained certifications such as China GMP, EU CEP, and US FDA for its production bases [3] - The company can produce various products from the same starting raw materials, enhancing market adaptability and reducing overall production costs [3] Group 4: Future Growth Points - The company anticipates stable growth from traditional products and collaborative development across its entire industry chain [4] - Ongoing projects, such as lithium hexafluorophosphate and lithium difluoro(oxalato)borate, are expected to be major growth drivers in the next three years [4] Group 5: Development Strategy - The company aims to enhance existing production facilities, improve management and R&D capabilities, and deepen relationships with key customers to ensure sustainable growth [4] - It plans to utilize its capital market advantages to pursue both organic growth and external expansion [4] Group 6: Pharmaceutical Sector Insights - The pharmaceutical segment is the highest revenue contributor and a key focus for future development [5] - The company is working on a model that integrates high-tech generic drugs and innovative drug CDMO business, enhancing its competitive edge [5] Group 7: Technological Advancements - The company has developed proprietary enzyme catalysis technologies that significantly improve production efficiency and reduce costs [6] - Collaborations with academic institutions have led to the development of patented intermediate enzyme catalysis technologies [6] Group 8: Regulatory Approvals - Recent FDA approvals for products like metoprolol tartrate and doxycycline capsules mark significant progress in the company's vertical integration from raw materials to formulations [7] - The approval of gabapentin capsules represents the first product chain achieving "raw material + formulation" integration [7] Group 9: Ongoing Projects - The Yongtai Handxin project is progressing well, with plans for GMP certification and production in 2021 [8] - The Inner Mongolia Yongtai project is also advancing, with a planned annual production capacity of 18,715 tons of fine chemicals and 30,000 tons of potassium fluoride [8]

Group 1: R&D Investment - The company's R&D investment is primarily allocated to new products, especially formulations, active pharmaceutical ingredients, and CF photoresist materials, aiming to explore new profit growth points and lay a foundation for future development [1] - The R&D efforts also focus on upgrading existing processes to enhance the market competitiveness of the company's products [1] Group 2: Production Capacity and Projects - The annual production capacity of 1,500 tons for CF photoresist has been accepted and completed, with ongoing communication with target customers as capacity is gradually released, which will significantly support the company's performance [1] - The lithium hexafluorophosphate project has completed trial production, with products passing customer verification and initial sales orders established, alongside the development of domestic and international sales channels [2] - The dual-fluoro project is progressing smoothly with equipment installation [2] Group 3: Market Expectations - The market demand for lithium hexafluorophosphate is expected to grow due to the increasing popularity of new energy vehicles and supporting infrastructure, along with the gradual implementation of national policies [2]